Zai Lab Limited announced that the National Medical Products Administration in China has approved the New Drug Application for AUGTYRO™ for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer.
Zai Lab Limited announced that the National Medical Products Administration in China has approved the New Drug Application for AUGTYRO™ for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer.